Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: First physiological data associated with a user during a first time period is received. The first physiological data is analyzed to determine (i) a first respiration rate for the first time period, (ii) a first plurality of sample heart rate values, and (iii) first heart rate variability parameters for the first time period. Second physiological data associated with the user during a second time period is received. The second physiological data is analyzed to determine (i) a second respiration rate for the second time period, (ii) a second plurality of sample heart rate values, and (iii) second heart rate variability parameters for the second time period, the second respiration rate being less than the first respiration rate. The percentage likelihood that the user has an untreated sleep disorder is determined based at least in part on the first heart rate variability parameters and the second heart rate variability parameters.

Abstract: Techniques for improved model-based predictions are provided. Patient data for a patient associated with a positive airway pressure (PAP) therapy is accessed, and a set of features is extracted from the patient data. A first predicted mouth leak measure is generated by processing the set of features using a leak model, and in response to determining that the first predicted mouth leak measure satisfies defined criteria, provisioning of a first PAP apparatus for the patient is facilitated.

Abstract: Provided are a pharmaceutical composition for wound healing including a surfactant, an antioxidant, a thickener, and SP, a method of treating a wound including administering the pharmaceutical composition to a subject, and a quasi-drug composition for wound healing including a surfactant, an antioxidant, a thickener, and substance. The pharmaceutical composition of the present invention reduces a wound size, generates new blood vessels, shows dermal and epidermal regeneration effects, matures granulation tissues, and synthesizes collagen, and thus may be used for wound healing.

Abstract: Provided are a pharmaceutical composition for wound healing including a surfactant, an antioxidant, a thickener, and SP, a method of treating a wound including administering the pharmaceutical composition to a subject, and a quasi-drug composition for wound healing including a surfactant, an antioxidant, a thickener, and substance. The pharmaceutical composition of the present invention reduces a wound size, generates new blood vessels, shows dermal and epidermal regeneration effects, matures granulation tissues, and synthesizes collagen, and thus may be used for wound healing.